Media headlines about Thermo Fisher Scientific (NYSE:TMO) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Thermo Fisher Scientific earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.995962429526 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several equities research analysts have recently commented on the company. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Barclays reissued an “overweight” rating and issued a $215.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. Argus reissued a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Jefferies Group reissued a “hold” rating and issued a $195.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $220.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $205.71.

Shares of Thermo Fisher Scientific (TMO) traded down $0.56 during trading on Friday, reaching $192.20. The company’s stock had a trading volume of 1,335,426 shares, compared to its average volume of 1,336,481. Thermo Fisher Scientific has a fifty-two week low of $139.32 and a fifty-two week high of $201.20. The firm has a market cap of $77,297.88, a P/E ratio of 21.18, a price-to-earnings-growth ratio of 1.76 and a beta of 1.07. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. During the same quarter last year, the firm posted $2.03 EPS. The company’s quarterly revenue was up 13.9% on a year-over-year basis. sell-side analysts expect that Thermo Fisher Scientific will post 9.36 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.19%.

In other news, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the sale, the chief executive officer now owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Peter E. Hornstra sold 3,894 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total value of $721,090.92. Following the sale, the vice president now directly owns 19,751 shares of the company’s stock, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Thermo Fisher Scientific (TMO) Receives Media Impact Score of 0.14” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/02/thermo-fisher-scientific-tmo-receives-media-impact-score-of-0-14.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.